Your browser doesn't support javascript.
loading
Trends in the overall survival rates in women with advanced ovarian cancer in a single tertiary centre in New Zealand.
Yeoh, Sara; Simcock, Bryony; Innes, Carrie; Mclachlan, Jennifer; Harker, Dianne; Sykes, Peter.
Afiliação
  • Yeoh S; Department of Obstetrics and Gynaecology, Christchurch Women's Hospital, Christchurch, New Zealand.
  • Simcock B; Department of Obstetrics and Gynaecology, Christchurch Women's Hospital, Christchurch, New Zealand.
  • Innes C; University of Otago, Christchurch, New Zealand.
  • Mclachlan J; Department of Medical Oncology, Christchurch Hospital, Christchurch, New Zealand.
  • Harker D; University of Otago, Christchurch, New Zealand.
  • Sykes P; Department of Obstetrics and Gynaecology, Christchurch Women's Hospital, Christchurch, New Zealand.
Aust N Z J Obstet Gynaecol ; 59(6): 861-866, 2019 12.
Article em En | MEDLINE | ID: mdl-31596958
ABSTRACT

BACKGROUND:

Survival rates for women diagnosed with ovarian cancer are much poorer than other gynaecological cancers and greatly depend on stage at diagnosis. A recent publication showed that unlike some other developed countries, there has been no improvement in the five-year survival rate for those diagnosed with ovarian cancer in New Zealand.

AIM:

To compare the five-year survival rate of women diagnosed with advanced ovarian cancer in a single tertiary hospital during two 36-month time periods 10 years apart. MATERIALS AND

METHODS:

An observational retrospective review of patient clinical notes, including all women diagnosed with stage three or four ovarian cancer between 2000 and 2002 (Cohort 1) and 2010-2012 (Cohort 2). Eligible patients were identified through the Regional Gynaecology Oncology database. Clinical notes were reviewed to compare the five-year survival rate between these two time periods and look at changes in patterns of care over time.

RESULTS:

Eighty-three women were diagnosed in 2000-2002 and 125 women in 2010-2012. There was no difference in five-year survival between cohorts (21.7% vs 23.2%, P = 0.80). Mean age at diagnosis did not differ between cohorts (62.1 years vs 63.5 years, P = 0.43); however, there were more women with stage four cancer in Cohort 2 (14% vs 30%, P = 0.01). In Cohort 2, more women were treated with neoadjuvant chemotherapy (20% vs 34%, P = 0.04) or chemotherapy only (6% vs 18%, P = 0.01).

CONCLUSION:

Five-year overall survival in women diagnosed with advanced ovarian cancer in our centre has not changed over the last 10 years.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Oceania Idioma: En Revista: Aust N Z J Obstet Gynaecol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Oceania Idioma: En Revista: Aust N Z J Obstet Gynaecol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Nova Zelândia